Joshua Ofman Sells 690 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) President Joshua Ofman sold 690 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $53.01, for a total transaction of $36,576.90. Following the sale, the president owned 435,818 shares in the company, valued at approximately $23,102,712.18. This trade represents a 0.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

GRAIL Stock Performance

Shares of NASDAQ:GRAL opened at $48.67 on Wednesday. The firm has a market capitalization of $1.90 billion, a PE ratio of -4.35 and a beta of 5.18. GRAIL, Inc. has a 52-week low of $20.44 and a 52-week high of $118.84. The firm has a fifty day moving average of $87.41 and a 200 day moving average of $78.10.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.33) by $0.89. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%.The business had revenue of $43.60 million for the quarter, compared to the consensus estimate of $43.33 million. On average, sell-side analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Institutional Trading of GRAIL

Institutional investors have recently made changes to their positions in the stock. N.E.W. Advisory Services LLC bought a new position in shares of GRAIL in the fourth quarter worth approximately $26,000. Comerica Bank raised its holdings in GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after buying an additional 173 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in GRAIL during the 4th quarter valued at $28,000. Elyxium Wealth LLC purchased a new stake in GRAIL during the 4th quarter valued at $31,000. Finally, Intesa Sanpaolo S.p.A. bought a new stake in GRAIL in the 4th quarter worth $44,000.

Analysts Set New Price Targets

Several analysts have issued reports on GRAL shares. Robert W. Baird set a $82.00 target price on GRAIL in a research note on Friday, February 20th. Guggenheim lifted their price target on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Morgan Stanley lowered their price objective on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Finally, TD Cowen initiated coverage on shares of GRAIL in a research report on Thursday, February 19th. They issued a “hold” rating and a $114.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $90.17.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Institutions adding stakes: Several large funds materially increased positions in Q4 (Farallon, Morgan Stanley, State Street, Baker Bros.), signaling confidence from sophisticated investors and providing a steady demand base. MarketBeat institutional ownership summary
• Positive Sentiment: Recent quarterly results beat EPS estimates (reported ($2.44) vs consensus ($3.33)) and revenue was roughly in line, which supports the case that core business traction (Galleri test adoption) is progressing. (Market reaction is mixed given continued multi-year losses.) Earnings & analyst summary
• Neutral Sentiment: Mixed analyst activity: Some firms trimmed price targets (Morgan Stanley cut to $60, Canaccord lowered targets), while others remain bullish (Guggenheim raised its target earlier). Overall consensus remains around a “Hold” with divergent price targets, adding to uncertainty on near-term direction. Analyst notes
• Negative Sentiment: Short interest jumped in February to ~6.3M shares (16.2% of float), up ~15% from mid‑February; days-to-cover ~1.9. A higher short percent increases downward pressure and volatility, especially given GRAL’s high beta. (Elevated shorting can amplify declines while also enabling short‑squeeze risk.)
• Negative Sentiment: Insider selling by top executives: CEO Robert Ragusa, President Joshua Ofman and CFO Aaron Freidin reported multiple sales in early March (CEO sale filings: Read More.; President filings: Read More.; CFO filings: Read More.). While sizes are modest vs. their holdings, clustered executive sales can spook investors and weigh on sentiment. InsiderTrades article

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.